0.00Open0.00Pre Close0 Volume0 Open Interest75.00Strike Price0.00Turnover266.24%IV-67.99%PremiumJan 17, 2025Expiry Date159.28Intrinsic Value100Multiplier12DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9950Delta0.0001Gamma1.47Leverage Ratio-0.0699Theta0.0248Rho1.46Eff Leverage0.0062Vega
Alnylam Pharmaceuticals Stock Discussion
Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 | ALNY Stock News
ALNY BUY ALERT 🚨 DRUG NEWS MULTIPLE PRICE TARGET RAISES
No comment yet